Compare ALGM & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALGM | ERAS |
|---|---|---|
| Founded | 1990 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 5.5B |
| IPO Year | 2007 | 2021 |
| Metric | ALGM | ERAS |
|---|---|---|
| Price | $37.58 | $17.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 12 |
| Target Price | ★ $44.27 | $12.08 |
| AVG Volume (30 Days) | 1.7M | ★ 4.8M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 36.23 |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $725,006,000.00 | N/A |
| Revenue This Year | $24.21 | N/A |
| Revenue Next Year | $17.93 | N/A |
| P/E Ratio | $3,703.00 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.39 | $1.06 |
| 52 Week High | $43.86 | $18.20 |
| Indicator | ALGM | ERAS |
|---|---|---|
| Relative Strength Index (RSI) | 63.65 | 62.62 |
| Support Level | $29.55 | $1.57 |
| Resistance Level | $38.15 | N/A |
| Average True Range (ATR) | 1.65 | 1.03 |
| MACD | 0.88 | 0.07 |
| Stochastic Oscillator | 88.96 | 73.62 |
Allegro Microsystems Inc is a designer, developer, fabless manufacturer, and marketer of sensor ICs and application-specific analog power ICs for automotive and industrial markets. Its Sensor IC allows customers to precisely measure motion, speed, position, and current, and Power ICs include high-temperature and high-voltage capable motor drivers, power management, and LED driver ICs. Its products are divided into three categories such as SENSE which includes Current Sensors, Switches and Latches, and Interface ICs among others; REGULATE which includes Regulators, ClearPower Modules, and LED Drivers; and DRIVE which includes BLDC Drivers, Brush DC, and others. Key revenue for the company is generated from Greater China and the rest from the United States, Japan, Europe, and other regions.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.